scholarly journals Affinity improvement of a therapeutic antibody to methamphetamine and amphetamine through structure-based antibody engineering

2014 ◽  
Vol 4 (1) ◽  
Author(s):  
Shraddha Thakkar ◽  
Nisha Nanaware-Kharade ◽  
Reha Celikel ◽  
Eric C. Peterson ◽  
Kottayil I. Varughese
Keyword(s):  
Antibody Engineering ◽  
Therapeutic Antibody

Therapeutic antibody engineering

2012 ◽  
Author(s):  
William R. Strohl ◽  
Lila M. Strohl
Keyword(s):  
Antibody Engineering ◽  
Therapeutic Antibody

Therapeutic antibody engineering by high efficiency cell screening

FEBS Letters ◽  
2013 ◽  
Vol 588 (2) ◽  
pp. 278-287 ◽  
Author(s):  
Achim Doerner ◽  
Laura Rhiel ◽  
Stefan Zielonka ◽  
Harald Kolmar
Keyword(s):  
High Efficiency ◽  
Antibody Engineering ◽  
Therapeutic Antibody

Deep mutational scanning for therapeutic antibody engineering

2021 ◽  
Author(s):  
Kyrin R. Hanning ◽  
Mason Minot ◽  
Annmaree K. Warrender ◽  
William Kelton ◽  
Sai T. Reddy
Keyword(s):  
Antibody Engineering ◽  
Therapeutic Antibody

scholarly journals Therapeutic antibody engineering

mAbs ◽  
2013 ◽  
Vol 5 (2) ◽  
pp. 175-177 ◽  
Author(s):  
Paul W.H.I. Parren ◽  
Alexey A. Lugovskoy
Keyword(s):  
Antibody Engineering ◽  
Therapeutic Antibody

scholarly journals Hapten engineering: Raising antibodies against the smallest of small molecules

2003 ◽  
Vol 25 (6) ◽  
pp. 35-37
Author(s):  
Andy Porter
Keyword(s):  
Drug Discovery ◽  
Drug Development ◽  
Small Molecules ◽  
Research Team ◽  
Antibody Engineering ◽  
Therapeutic Antibody ◽  
Protein Targets ◽  
Potential Success ◽  
Important Field ◽  
First Time

In recent years, antibody engineering has become one of the most important and most productive routes to drug discovery. It is now widely accepted that this approach can reduce development times and increase potential success, compared with classical drug development. Until recently, the isolation and production of therapeutic-antibody products has been concentrated on larger, protein targets. A research team at Haptogen has now overcome the significant technical difficulties that have been associated with raising antibodies to the smallest of small molecules — bioactive haptens — and, for the first time, anti-hapten therapeutics can be realized. Here, we outline our pioneering approach to antibody engineering and present the results of early work in the important field of anti-infective therapy.

Sign in / Sign up

Export Citation Format

Share Document